<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00670956</url>
  </required_header>
  <id_info>
    <org_study_id>10-03705</org_study_id>
    <nct_id>NCT00670956</nct_id>
  </id_info>
  <brief_title>Prenatal Steroids for Treatment of Congenital Cystic Adenomatoid Malformations (CCAM)</brief_title>
  <acronym>CCAM Steroids</acronym>
  <official_title>Investigation of Prenatal Steroids for Treatment of Prenatally Diagnosed CCAMs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Congenital cystic adenomatoid malformations (CCAMs) are theorized to be growing immature lung
      tissue. Administration of maternal steroids in the mid-trimester may stop the growth or
      decrease the size of the CCAM, thus increasing normal lung tissue and improving survival in
      fetuses with large CCAMs. This is a prospective, blinded, randomized trial comparing
      administration of a single course of antenatal steroids (Betamethasone) to control (i.e.,
      placebo). The primary outcome variable will be incidence of hydrops. One month postnatal
      survival and relative size of the CCAM as determined by CCAM volume:head circumference ratio
      (CVR) between treatment/no treatment groups will be secondary outcome variables. Change in
      size of CCAM will be serially followed for both groups with individual growth curves being
      plotted prenatally and these will be compared with pathology weigh and volume to evaluate
      treatment effect. Other prenatal data collected will include: incidence of polyhydramnios,
      incidence of premature rupture of membranes, incidence of material complications. We will
      also compare mode of delivery, postnatal respiratory compromise, need for resection in the
      first week of life, and occurrence of complications during newborn administration
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recruitment has been poor. Study drug is being offered as part of standard care of women
    carrying a pregnancy diagnosed with CCAM
  </why_stopped>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Hydrops Fetalis</measure>
    <time_frame>Delivery, up to approximately 20 weeks post-enrollment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of CCAM Size in Mid-trimester Fetuses (Study/Administration vs Control/Placebo)</measure>
    <time_frame>Baseline, Delivery (up to approximately 20 weeks post-enrollment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival at One-month Between Study and Control Groups.</measure>
    <time_frame>30 days after delivery (up to approximately 24 weeks post-enrollment)</time_frame>
    <description>Status of neonate survival 30 days after delivery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Congenital Cystic Adenomatoid Malformation</condition>
  <arm_group>
    <arm_group_label>Active Study Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>STEROID: Betamethasone; 12 mg intramuscularly x 2 doses 24 hours apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PLACEBO: IM x 2 doses 24 hours apart</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betamethasone</intervention_name>
    <description>12 mg intramuscularly x 2 doses 24 hours apart</description>
    <arm_group_label>Active Study Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>PLACEBO: IM x 2 doses 24 hours apart</description>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  GA &lt; 26 weeks

          -  Maternal age &gt; 18 years of age

          -  Singleton pregnancy

          -  Normal chromosomes

          -  CCAM volume to head circumference ratio (CVR) &gt; 1.4

          -  No maternal medical/surgical contraindications

          -  No evidence of hydrops

          -  Not previously randomization

        Exclusion Criteria:

          -  Maternal diabetes or use of insulin

          -  Preterm labor

          -  Multiple congenital anomalies with CCAM

          -  Chromosomal anomaly with CCAM

          -  Multiple gestation pregnancy with CCAM

          -  Not willing to be randomized

          -  Unable or unwilling to return to UCSF for second dose of drug or placebo

          -  CVR &lt; 1.4
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy M Crombleholme, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Cincinnati</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Douglas Wilson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hanmin Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco Fetal Treatment Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fetalcarecenter.org/</url>
    <description>Fetal Care Center of Cincinnati Children's Hospital</description>
  </link>
  <link>
    <url>http://fetus.ucsfmedicalcenter.org/</url>
    <description>Fetal Treatment Center at the University of California, San Francisco</description>
  </link>
  <link>
    <url>http://www.chop.edu/consumer/jsp/division/service.jsp?id=27703</url>
    <description>Center for Fetal Diagnosis and Treatment, Children's Hospital of Philadelphia</description>
  </link>
  <reference>
    <citation>Vu L, Tsao K, Lee H, Nobuhara K, Farmer D, Harrison M, Goldstein RB. Characteristics of congenital cystic adenomatoid malformations associated with nonimmune hydrops and outcome. J Pediatr Surg. 2007 Aug;42(8):1351-6.</citation>
    <PMID>17706495</PMID>
  </reference>
  <reference>
    <citation>Schumacher A, Sidor J, Bühling KJ. [Continuous glucose monitoring using the glucose sensor CGMS in metabolically normal pregnant women during betamethasone therapy for fetal respiratory distress syndrome]. Z Geburtshilfe Neonatol. 2006 Oct;210(5):184-90. German.</citation>
    <PMID>17099841</PMID>
  </reference>
  <reference>
    <citation>Peltoniemi OM, Kari MA, Tammela O, Lehtonen L, Marttila R, Halmesmäki E, Jouppila P, Hallman M; Repeat Antenatal Betamethasone Study Group. Randomized trial of a single repeat dose of prenatal betamethasone treatment in imminent preterm birth. Pediatrics. 2007 Feb;119(2):290-8.</citation>
    <PMID>17272618</PMID>
  </reference>
  <reference>
    <citation>Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2006 Jul 19;(3):CD004454. Review. Update in: Cochrane Database Syst Rev. 2017 Mar 21;3:CD004454.</citation>
    <PMID>16856047</PMID>
  </reference>
  <reference>
    <citation>Neilson JP. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Obstet Gynecol. 2007 Jan;109(1):189-90.</citation>
    <PMID>17233108</PMID>
  </reference>
  <reference>
    <citation>Tsao K, Hawgood S, Vu L, Hirose S, Sydorak R, Albanese CT, Farmer DL, Harrison MR, Lee H. Resolution of hydrops fetalis in congenital cystic adenomatoid malformation after prenatal steroid therapy. J Pediatr Surg. 2003 Mar;38(3):508-10. Review.</citation>
    <PMID>12632377</PMID>
  </reference>
  <reference>
    <citation>Arca MJ, Teich S. Current controversies in perinatal care: fetal versus neonatal surgery. Clin Perinatol. 2004 Sep;31(3):629-48. Review.</citation>
    <PMID>15325542</PMID>
  </reference>
  <reference>
    <citation>Wilson RD, Baxter JK, Johnson MP, King M, Kasperski S, Crombleholme TM, Flake AW, Hedrick HL, Howell LJ, Adzick NS. Thoracoamniotic shunts: fetal treatment of pleural effusions and congenital cystic adenomatoid malformations. Fetal Diagn Ther. 2004 Sep-Oct;19(5):413-20.</citation>
    <PMID>15305098</PMID>
  </reference>
  <reference>
    <citation>Knox EM, Kilby MD, Martin WL, Khan KS. In-utero pulmonary drainage in the management of primary hydrothorax and congenital cystic lung lesion: a systematic review. Ultrasound Obstet Gynecol. 2006 Oct;28(5):726-34. Review.</citation>
    <PMID>17001747</PMID>
  </reference>
  <reference>
    <citation>Davenport M, Warne SA, Cacciaguerra S, Patel S, Greenough A, Nicolaides K. Current outcome of antenally diagnosed cystic lung disease. J Pediatr Surg. 2004 Apr;39(4):549-56. Review.</citation>
    <PMID>15065026</PMID>
  </reference>
  <reference>
    <citation>Miller JA, Corteville JE, Langer JC. Congenital cystic adenomatoid malformation in the fetus: natural history and predictors of outcome. J Pediatr Surg. 1996 Jun;31(6):805-8.</citation>
    <PMID>8783108</PMID>
  </reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2008</study_first_submitted>
  <study_first_submitted_qc>May 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2008</study_first_posted>
  <results_first_submitted>March 18, 2015</results_first_submitted>
  <results_first_submitted_qc>March 18, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 30, 2015</results_first_posted>
  <last_update_submitted>March 18, 2015</last_update_submitted>
  <last_update_submitted_qc>March 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prenatal steroids</keyword>
  <keyword>hydrops</keyword>
  <keyword>congenital cystic adenomatoid malformation of the lung</keyword>
  <keyword>prenatal intervention</keyword>
  <keyword>betamethasone</keyword>
  <keyword>prenatal diagnosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Congenital Abnormalities</mesh_term>
    <mesh_term>Cystic Adenomatoid Malformation of Lung, Congenital</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Betamethasone benzoate</mesh_term>
    <mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Betamethasone Valerate</mesh_term>
    <mesh_term>Betamethasone sodium phosphate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Only one participant was enrolled to the study before it was terminated; no participants were enrolled to the control arm</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Active Study Group</title>
          <description>STEROID: Betamethasone; 12 mg intramuscularly x 2 doses 24 hours apart
Betamethasone: 12 mg intramuscularly x 2 doses 24 hours apart</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Only one participant was enrolled to the study before it was terminated; no participants were enrolled to the control arm</population>
      <group_list>
        <group group_id="B1">
          <title>Active Study Group</title>
          <description>STEROID: Betamethasone; 12 mg intramuscularly x 2 doses 24 hours apart
Betamethasone: 12 mg intramuscularly x 2 doses 24 hours apart</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Hydrops Fetalis</title>
        <time_frame>Delivery, up to approximately 20 weeks post-enrollment</time_frame>
        <population>Only one participant was enrolled to the study before it was terminated; no participants were enrolled to the control arm</population>
        <group_list>
          <group group_id="O1">
            <title>Active Study Group</title>
            <description>STEROID: Betamethasone; 12 mg intramuscularly x 2 doses 24 hours apart
Betamethasone: 12 mg intramuscularly x 2 doses 24 hours apart</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Hydrops Fetalis</title>
          <population>Only one participant was enrolled to the study before it was terminated; no participants were enrolled to the control arm</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of CCAM Size in Mid-trimester Fetuses (Study/Administration vs Control/Placebo)</title>
        <time_frame>Baseline, Delivery (up to approximately 20 weeks post-enrollment)</time_frame>
        <population>Study was terminated without enrollment to control arm; therefore, no comparison was made</population>
        <group_list>
          <group group_id="O1">
            <title>Active Study Group</title>
            <description>STEROID: Betamethasone; 12 mg intramuscularly x 2 doses 24 hours apart
Betamethasone: 12 mg intramuscularly x 2 doses 24 hours apart</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of CCAM Size in Mid-trimester Fetuses (Study/Administration vs Control/Placebo)</title>
          <population>Study was terminated without enrollment to control arm; therefore, no comparison was made</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Survival at One-month Between Study and Control Groups.</title>
        <description>Status of neonate survival 30 days after delivery</description>
        <time_frame>30 days after delivery (up to approximately 24 weeks post-enrollment)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Study Group</title>
            <description>STEROID: Betamethasone; 12 mg intramuscularly x 2 doses 24 hours apart
Betamethasone: 12 mg intramuscularly x 2 doses 24 hours apart</description>
          </group>
        </group_list>
        <measure>
          <title>Survival at One-month Between Study and Control Groups.</title>
          <description>Status of neonate survival 30 days after delivery</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days post-delivery (up to approximately 24 weeks)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Active Study Group</title>
          <description>STEROID: Betamethasone; 12 mg intramuscularly x 2 doses 24 hours apart
Betamethasone: 12 mg intramuscularly x 2 doses 24 hours apart</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Hanmin Lee, MD</name_or_title>
      <organization>University of California San Francisco</organization>
      <phone>415-476-4086</phone>
      <email>hanmin.lee@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

